Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 12/20 | 0.35 |
| ▸ | CES1 | P23141 | 7/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | PLA2G4C | Q9UP65 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7708913 | 0.88 | EPHX1 (0.48) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL420349 | 0.86 | EPHX1 (0.52) | EPHX1ALDH1A1MEN1KMT2AFAAH | |
| SCHEMBL7716898 | 0.84 | EPHX1 (0.42) | EPHX1CA2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL1556242 | 0.80 | CYP3A4 (0.33) | ALDH1A1POLBCYP1A2 | |
| SCHEMBL8791516 | 0.77 | LMNA (0.31) | HSD17B10 | |
| SCHEMBL998029 | 0.77 | — | — | |
| SCHEMBL7463705 | 0.72 | — | — | |
| SCHEMBL1417076 | 0.71 | POLB (0.37) | ALDH1A1POLB | |
| SCHEMBL1416650 | 0.70 | — | — | |
| SCHEMBL3248298 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2088865-B1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2015-10-21 | — | — | EP | claimed |
| US-8557801-B2 | Compounds and compositions useful for the treatment of parasitic diseases | IRM LLC (BM) | 2013-10-15 | — | — | US | claimed |
| EP-2451814-A2 | FUSED IMIDAZOLES AND COMPOSITIONS COMPRISING THEM FOR THE TREATMENT OF PARASITIC DISEASES, SUCH AS E.G. MALARIA | IRM LLC (BM) | 2012-05-16 | — | — | EP | claimed |
| US-7943758-B2 | 3′-end nucleoside unit comprising phosphoramidite | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-05-17 | — | — | US | claimed |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-03-10 | — | — | US | claimed |
| WO-2011006143-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-01-13 | — | — | WO | claimed |
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | JINA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | claimed |
| US-20080039620-A1 | 3'-End Nucleoside Unit Comprising Phosphoramidite | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-02-14 | — | — | US | claimed |
| EP-1719778-A1 | 3'-TERMINAL NUCLEOSIDE UNIT CONTAINING PHOSPHORAMIDITE | Japan Science and Technology Agency (JP) | 2006-11-08 | — | — | EP | claimed |
| US-9963454-B2 | Compounds and compositions for the treatment of parasitic disease | NOVARTIS AG (CH) | 2018-05-08 | — | — | US | disclosed |
| US-9637515-B2 | Guggulphospholipid methods and compositions | JINA PHARMACEUTICALS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9469645-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-20160108051-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| EP-2737927-B1 | Imidazo[1,2a]pyrazines and compositions comprising them for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-03-30 | — | — | EP | disclosed |
| EP-1243594-A1 | Process for crystallizing N2-((S)-1-ethoxycarbonyl-3-phenylpropyl)-N6-trifluoroacetyl-L-lysyl-L-proline | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6369101-B1 | Therapeutic method to treat herpes virus infection | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2002-04-09 | — | — | US | disclosed |
| US-5801251-A | Process for crystallizing N2 -((S)-1-ethoxycarbonyl-3-phenylpropyl)-N6 -trifluoroacetyl-L-lysyl-L-proline | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-09-01 | — | — | US | disclosed |
| WO-1998034603-A1 | USE OF BETULIN AND ANALOGS THEREOF TO TREAT HERPESVIRUS INFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-08-13 | — | — | WO | disclosed |
| US-5519146-A | MIXTURE OF SOLVENTS, INTERMEDIATE FOR ANGIOTENSIN CONVERTING ENZYME INHIBITOR | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1996-05-21 | — | — | US | disclosed |
| EP-0645398-A1 | METHOD OF CRYSTALLIZING N?2 -((S)-1-ETHOXYCARBONYL-3-PHENYLPROPYL)-N?6 -TRIFLUOROACETYL-L-LYSYL-L-PROLINE | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1995-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | SGMS2, SGMS1, PLA2G5 | EPHX1 141/4885CA2 4036/4885ALDH1A1 4045/4885 |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, SGMS2, FDPS | EPHX1 44/4885CA2 1439/4885ALDH1A1 1414/4885 |
| US-20160108051-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASE | SQLE, SGMS2, SGMS1 | EPHX1 19/4885CA2 1470/4885ALDH1A1 2013/4885 |
| US-20080039620-A1 | 3'-End Nucleoside Unit Comprising Phosphoramidite | POLR2H, POLN, RNGTT | EPHX1 2863/4885CA2 2861/4885ALDH1A1 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.